SPDR S&P Biotech (ETF)’s Stock Is Buy After Today’s Bullish Options Activity – FinancialMagazin.com

This post was originally published on this site

Share with your friends

In today’s session SPDR S&P Biotech (ETF) (XBI) registered an unusually high (1,587) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2015 call, expecting serious XBI increase. With 1,587 contracts traded and 3616 open interest for the Nov, 15 contract, it seems this is a quite bullish bet. The option with symbol: XBI151120C00070000 closed last at: $0.05 or 87.5% down. The ETF increased 0.49% or $0.34 on November 20, hitting $69.58. SPDR S&P Biotech (ETF) (NYSEARCA:XBI) has declined 70.13% since April 21, 2015 and is downtrending. It has underperformed by 69.22% the S&P500.

SPDR S&P Biotech ETF seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The ETF has a market cap of $2.13 billion. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. It has 3.82 P/E ratio. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

SPDR S&P Biotech – Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.